Home
News & Events
RECORDATI: TO BE HIGHLIGHTED AT AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGY (AACE) ANNUAL MEETING
RECORDATI: FDA GRANTS ISTURISA® (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING’S SYNDROME
RECORDATI RARE DISEASES TO PRESENT NEW DATA IN CUSHING’S DISEASE AND CUSHING’S SYNDROME AT ENDO 2024
About Us
Recordati Rare Diseases develops high-impact therapies for devastating rare diseases. At Recordati, we focus on the few - those affected by rare diseases. They are our top priority and at the core of everything we do.
